Omnicell Inc provides automation and business analytics software for healthcare providers. The company is engaged in transforming the pharmacy and nursing care delivery model. The company helps its customers define and deliver cost-effective medication management designed to equip and empower pharmacists and nurses to focus on patient care rather than administrative tasks and drive improved clinical, operational, and financial outcomes across all care settings. The company derives the majority of its revenue from the United States.
The chart shows the growth of an initial investment of $10,000 in Omnicell Inc, comparing it to the performance of the S&P 500 index.
All prices have been adjusted for splits and dividends.
Omnicell Inc (OMCL) has returned -24.61% so far this year and 7.32% over the past 12 months. Looking at the last ten years, OMCL has achieved an annualized return of 2.04%, underperforming the Benchmark (SPY), which averaged 12.23% per year.
The table below presents the monthly returns of Omnicell Inc (OMCL) with color gradation from worst to best to easily spot seasonal factors.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 7.06% | -16.28% | -16.82% | 1.04% | ||||||||
| 2025 | 0.49% | -14.24% | -7.98% | -8.78% | -3.13% | -2.46% | 5.91% | 6.09% | -5.41% | 10.61% | 8.76% | 24.76% |
| 2024 | -14.12% | -19.34% | 10.30% | -8.50% | 21.24% | -17.57% | 7.95% | 38.44% | -0.93% | 12.13% | -5.59% | -4.73% |
| 2023 | 8.76% | -1.23% | 5.62% | 3.83% | 20.76% | 0.35% | -13.67% | -9.80% | -21.15% | -20.93% | -5.66% | 13.51% |
| 2022 | -16.78% | -14.66% | 0.83% | -16.55% | 2.30% | 2.10% | -3.17% | -6.52% | -14.09% | -11.61% | -34.51% | -1.93% |
| 2021 | -1.52% | 7.31% | 0.89% | 11.00% | -4.14% | 8.90% | -3.10% | 6.03% | -4.72% | 19.41% | -0.84% | -2.46% |
| 2020 | -0.88% | -0.01% | -19.89% | 15.68% | -6.77% | 6.20% | -0.92% | -5.75% | 12.19% | 15.06% | 20.16% | 13.69% |
| 2019 | 8.08% | 29.69% | -5.25% | -1.18% | -1.37% | 8.04% | -14.28% | -4.69% | 1.49% | -3.14% | 12.92% | 2.43% |
| 2018 | 0.62% | -10.09% | -0.80% | -0.35% | 8.13% | 11.95% | 14.20% | 15.26% | 5.04% | -1.67% | 9.28% | -22.17% |
| 2017 | 4.36% | 5.62% | 6.27% | 1.85% | -3.74% | 7.48% | 14.68% | 3.53% | -0.39% | -2.26% | 4.90% | -7.62% |
| 2016 | 15.52% | 1.92% | 6.50% | 13.50% | -2.87% | 1.65% | -14.01% | 10.14% | -4.91% |
The charts below present risk-adjusted performance metrics for Omnicell Inc (OMCL) and compare them to a Benchmark (SPY). These indicators evaluate an investment's returns against its associated risks.
The Sharpe ratio helps investors understand how much return they're getting for the level of risk taken. A higher Sharpe ratio indicates better risk-adjusted performance, meaning more reward for each unit of risk.
These values reflect how efficiently the investment has delivered returns relative to its volatility over different time periods. All figures are annualized and based on daily total returns.
The chart below shows the rolling Sharpe ratio of OMCL compared to the benchmark. This view highlights how the investment's risk-adjusted performance has changed over time.
The current Omnicell Inc volatility is 2.82%, representing the standart deviation of percentage change in the investments's value, either up or down over the past month. The chart below shows the rolling one-month volatility.
The Drawdowns chart displays portfolio losses from any high point along the way. It shows the maximum percentage drop from a peak to a trough over a specified period, indicating the risk of significant losses.
Although chart shows positive values, it represents the percentage drop from the peak, so a value of 10% means the portfolio has dropped 10% from its highest point.
The income statement provides a summary of a company's revenues, expenses, and profits over a specific period. It shows how much money the company earned (revenues) and how much it spent (expenses), leading to the net income or profit. This statement is crucial for understanding a company's financial performance and profitability.
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Liabilities And Equity (USD) | 1.97B | 2.12B | 2.23B | 2.21B | 2.14B | 1.82B | 1.24B | 1.08B | 980.30M | 935.10M | 578.75M | 560.21M | 492.50M | 441.82M | 362.09M |
| Equity Attributable To Parent (USD) | 1.23B | 1.24B | 1.19B | 1.13B | 1.15B | 967.50M | 845.25M | 679.62M | 517.20M | 431.61M | 402.39M | 390.10M | 349.00M | 307.55M | 282.91M |
| Equity Attributable To Noncontrolling Interest (USD) | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Equity (USD) | 1.23B | 1.24B | 1.19B | 1.13B | 1.15B | 967.50M | 845.25M | 679.62M | 517.20M | 431.61M | 402.39M | 390.10M | 349.00M | 307.55M | 282.91M |
| Other Non-current Liabilities (USD) | - | - | - | - | - | - | 108.56M | - | - | - | - | - | - | - | - |
| Long-term Debt (USD) | - | - | - | - | - | - | 50.00M | - | - | - | - | - | - | - | - |
| Noncurrent Liabilities (USD) | 266.30M | 281.97M | 670.13M | 652.18M | 119.65M | 580.58M | 158.56M | 197.05M | 250.57M | 322.58M | 51.73M | 57.79M | 51.10M | 51.19M | 20.31M |
| Other Current Liabilities (USD) | 375.45M | 483.59M | 271.01M | 291.60M | 733.52M | 180.36M | 146.46M | 124.88M | 137.01M | 127.12M | 83.79M | 73.02M | 56.33M | 53.21M | 40.54M |
| Wages (USD) | 57.17M | 60.31M | 51.75M | 73.46M | 71.13M | 55.75M | 44.16M | 41.66M | 27.24M | 26.72M | 18.20M | 19.87M | 19.60M | 11.61M | 7.33M |
| Accounts Payable (USD) | 43.99M | 51.78M | 45.03M | 63.39M | 71.51M | 40.31M | 46.38M | 38.04M | 48.29M | 27.07M | 22.65M | 19.43M | 16.47M | 18.26M | 11.00M |
| Current Liabilities (USD) | 476.61M | 595.68M | 367.79M | 428.45M | 876.16M | 276.42M | 237.00M | 204.58M | 212.54M | 180.91M | 124.63M | 112.33M | 92.40M | 83.08M | 58.87M |
| Liabilities (USD) | 742.91M | 877.65M | 1.04B | 1.08B | 995.81M | 857.00M | 395.56M | 401.63M | 463.11M | 503.50M | 176.36M | 170.12M | 143.50M | 134.27M | 79.18M |
| Other Non-current Assets (USD) | 1.00B | 1.00B | 979.53M | 992.08M | 1.01B | 767.81M | 529.60M | 488.92M | 402.48M | 577.68M | 282.31M | 240.65M | 223.47M | 226.96M | 62.95M |
| Non-current Prepaid Expenses (USD) | - | - | - | - | - | - | 48.86M | - | - | - | - | - | - | - | - |
| Intangible Assets (USD) | 170.11M | 188.27M | 211.17M | 242.91M | 277.62M | 168.21M | 124.87M | 143.69M | 168.11M | - | - | - | - | - | - |
| Fixed Assets (USD) | 120.11M | 112.69M | 108.60M | 93.96M | 71.14M | 59.07M | 54.25M | 51.50M | 42.60M | 42.01M | 32.31M | 36.18M | 35.25M | 34.11M | 17.31M |
| Noncurrent Assets (USD) | 1.29B | 1.31B | 1.30B | 1.33B | 1.36B | 995.09M | 757.57M | 684.11M | 613.18M | 619.70M | 314.62M | 276.83M | 258.72M | 261.06M | 80.26M |
| Other Current Assets (USD) | 328.60M | 444.49M | 539.48M | 407.72M | 397.39M | 526.97M | 142.39M | 275.57M | 234.92M | 217.47M | 197.95M | 228.31M | 183.44M | 138.46M | 253.23M |
| Prepaid Expenses (USD) | 33.71M | 25.94M | 25.97M | 27.07M | 22.50M | 16.03M | 14.48M | 20.70M | 36.06M | 28.65M | 19.59M | 23.52M | 18.88M | 15.39M | 10.50M |
| Inventory (USD) | 100.91M | 88.66M | 110.10M | 147.55M | 119.92M | 96.30M | 108.01M | 100.87M | 96.14M | 69.30M | 46.59M | 31.55M | 31.46M | 26.90M | 18.11M |
| Accounts Receivable (USD) | 216.86M | 256.40M | 252.03M | 299.47M | 240.89M | 190.12M | 218.36M | - | - | - | - | - | - | - | - |
| Current Assets (USD) | 680.07M | 815.49M | 927.57M | 881.81M | 780.70M | 829.41M | 483.24M | 397.13M | 367.12M | 315.41M | 264.13M | 283.38M | 233.78M | 180.76M | 281.83M |
| Assets (USD) | 1.97B | 2.12B | 2.23B | 2.21B | 2.14B | 1.82B | 1.24B | 1.08B | 980.30M | 935.10M | 578.75M | 560.21M | 492.50M | 441.82M | 362.09M |
Omnicell's EVP & Chief Legal/Admin Officer Corey Manley sold 6,106 shares worth $243,629 on December 3, 2025, reducing his direct holdings by 5.85%. The sale occurred as the stock approached 52-week highs following strong Q3 results and the announcement of the company's new Titan XT automated dispensing system, which prompted analyst upgrades.
Evoke Pharma partnered with EVERSANA and Omnicell to expand access to GIMOTI nasal spray for gastroparesis treatment, targeting large gastroenterology practices and specialty pharmacies through strategic pharmacy network agreements.
The global pharmacy automation market is projected to grow from USD 6.99 billion in 2025 to USD 16.65 billion by 2034, driven by technological advancements, chronic disease management, and the need to reduce medication errors.
Several mid-cap stocks, including Globalstar, V.F. Corp, and Madrigal Pharmaceuticals, were among the top gainers last week. The companies reported positive financial results and business updates, leading to the stock price increases.
The global adherence packaging market size is expected to grow from $1.10 billion in 2023 to $1.93 billion by 2032, driven by the increasing number of chronic diseases and the need for quality medication. However, high costs and strict regulations pose challenges to the market's growth.
A robust Advanced Services portfolio and strategic restructuring initiatives bode well for Omnicell (OMCL).
Inspire (INSP) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
With the EnlivenHealth platform, Omnicell (OMCL) is gaining momentum with cross-selling and up-selling communication solutions to existing customers.
Omnicell (OMCL) outpaces expectations in the first quarter of 2024 in a challenging customer environment.
Omnicell (OMCL) delivered earnings and revenue surprises of 137.50% and 4.43%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
